Literature DB >> 16053960

Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.

Steve R Ommen1, Barry J Maron, Iacopo Olivotto, Martin S Maron, Franco Cecchi, Sandro Betocchi, Bernard J Gersh, Michael J Ackerman, Robert B McCully, Joseph A Dearani, Hartzell V Schaff, Gordon K Danielson, A Jamil Tajik, Rick A Nishimura.   

Abstract

OBJECTIVES: This study sought to determine the impact of surgical myectomy on long-term survival in hypertrophic cardiomyopathy (HCM).
BACKGROUND: Left ventricular (LV) outflow tract obstruction in HCM increases the likelihood of heart failure and cardiovascular death. Although surgical myectomy is the primary treatment for amelioration of outflow obstruction and advanced drug-refractory heart failure symptoms, its impact on long-term survival remains unresolved.
METHODS: Total and HCM-related mortality were compared in three subgroups comprised of 1,337 consecutive HCM patients evaluated from 1983 to 2001: 1) surgical myectomy (n = 289); 2) LV outflow obstruction without operation (n = 228); and 3) nonobstructive (n = 820). Mean follow-up duration was 6 +/- 6 years.
RESULTS: Including two operative deaths (procedural mortality, 0.8%), 1-, 5-, and 10-year overall survival after myectomy was 98%, 96%, and 83%, respectively, and did not differ from that of the general U.S. population matched for age and gender (p = 0.2) nor from patients with nonobstructive HCM (p = 0.8). Compared to nonoperated obstructive HCM patients, myectomy patients experienced superior survival free from all-cause mortality (98%, 96%, and 83% vs. 90%, 79%, and 61%, respectively; p < 0.001), HCM-related mortality (99%, 98%, and 95% vs. 94%, 89%, and 73%, respectively; p < 0.001), and sudden cardiac death (100%, 99%, and 99% vs. 97%, 93%, and 89%, respectively; p = 0.003). Multivariate analysis showed myectomy to have a strong, independent association with survival (hazard ratio 0.43; p < 0.001).
CONCLUSIONS: Surgical myectomy performed to relieve outflow obstruction and severe symptoms in HCM was associated with long-term survival equivalent to that of the general population, and superior to obstructive HCM without operation. In this retrospective study, septal myectomy seems to reduce mortality risk in severely symptomatic patients with obstructive HCM.

Entities:  

Mesh:

Year:  2005        PMID: 16053960     DOI: 10.1016/j.jacc.2005.02.090

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  116 in total

1.  Perfecting patient-centered care: the needs of the patient come first.

Authors:  Henry H Ting; Steve R Ommen; David A Foley; Farris K Timimi; David L Hayes
Journal:  J Cardiovasc Transl Res       Date:  2008-10-07       Impact factor: 4.132

Review 2.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Charles J Knight
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

Review 3.  Management of hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore
Journal:  BMJ       Date:  2006-05-27

Review 4.  Surgery for heart failure.

Authors:  Stephen Large
Journal:  Heart       Date:  2007-03       Impact factor: 5.994

5.  Reoperative myectomy via the left ventricular apex in a patient with hypertrophic obstructive cardiomyopathy.

Authors:  Patrick Oellers; Shuab Omer; Gregor Makosch; Ramon Kumar; Haroon-Ur Rashid; Joseph P Navarijo; David A Ott
Journal:  Tex Heart Inst J       Date:  2010

6.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

7.  A new technique to avoid the intraoperative complications of septal myectomy in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Oguz Omay; Emre Ozker; Serdar Celebi; Kaya Suzer; Ilhan Ozgol
Journal:  Heart Vessels       Date:  2009-01-23       Impact factor: 2.037

Review 8.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

9.  Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients.

Authors:  Antonio Berruezo; Markus Linhart; Angelo Auricchio; José Luis Zamorano; Pilar Santamaria; Roger Borràs; Felip Burgos; Josep Brugada
Journal:  J Interv Card Electrophysiol       Date:  2018-02-03       Impact factor: 1.900

10.  Surgical management of hypertrophic cardiomyopathy in 2007: what is new?

Authors:  Morgan L Brown; Hartzell V Schaff
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.